Julius Knowles - Nov 1, 2021 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Director
Signature
/s/ Keith Regnante, Attorney-in-Fact
Stock symbol
KROS
Transactions as of
Nov 1, 2021
Transactions value $
-$2,007,129
Form type
4
Date filed
11/3/2021, 07:04 PM
Previous filing
Oct 21, 2021
Next filing
Dec 3, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KROS Common Stock Sale -$295K -7.06K -1.65% $41.85 421K Nov 1, 2021 See footnote F1, F2, F3
transaction KROS Common Stock Sale -$192K -4.6K -1.59% $41.85 285K Nov 1, 2021 See footnote F1, F2, F4
transaction KROS Common Stock Sale -$312K -7.35K -1.75% $42.43 414K Nov 1, 2021 See footnote F1, F3, F5
transaction KROS Common Stock Sale -$204K -4.8K -1.69% $42.43 280K Nov 1, 2021 See footnote F1, F4, F5
transaction KROS Common Stock Sale -$137K -3.25K -0.79% $42.10 410K Nov 2, 2021 See footnote F1, F3, F6
transaction KROS Common Stock Sale -$89.3K -2.12K -0.76% $42.10 278K Nov 2, 2021 See footnote F1, F4, F6
transaction KROS Common Stock Sale -$65.3K -1.52K -0.37% $43.04 409K Nov 2, 2021 See footnote F1, F3, F7
transaction KROS Common Stock Sale -$42.7K -991 -0.36% $43.04 277K Nov 2, 2021 See footnote F1, F4, F7
transaction KROS Common Stock Sale -$253K -6.07K -1.48% $41.65 403K Nov 3, 2021 See footnote F1, F3, F8
transaction KROS Common Stock Sale -$165K -3.96K -1.43% $41.65 273K Nov 3, 2021 See footnote F1, F4, F8
transaction KROS Common Stock Sale -$153K -3.6K -0.89% $42.45 399K Nov 3, 2021 See footnote F1, F3, F9
transaction KROS Common Stock Sale -$99.6K -2.35K -0.86% $42.45 270K Nov 3, 2021 See footnote F1, F4, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.18 to $42.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8) and (9).
F3 The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I.
F4 The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.18 to $42.95 inclusive.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.55 to $42.49 inclusive.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.55 to $43.20 inclusive.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.18 to $42.17 inclusive.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.18 to $42.81 inclusive.